Publications

Janjua M, Badshah A, Matta F, Danescu LG, Yaekoub AY, Stein PD.
Treatment of acute pulmonary embolism as outpatients or following early discharge. A systematic review.
Thromb Haemost. 2008 Nov;100(5):756-61.

Roldán V, Marín F.
Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody.
Thromb Haemost. 2008 Nov;100(5):754-5.

Nieto JA, Camara T, Gonzalez-Higueras E, Ruiz-Gimenez N, Guijarro R, Marchena PJ, Monreal M; for the RIETE Investigators.
Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry.
Thromb Haemost. 2008;100(5):789-796.

Levy JH, Tanaka KA, Dietrich W.
Perioperative hemostatic management of patients treated with vitamin K antagonists
Anesthesiology. 2008 Nov;109(5):918-26

Conget F, Otero R, Jiménez D, Martí D, Escobar C, Rodríguez C, Uresandi F, Cabezudo MA, Nauffal D, Oribe M, Yusen R.
Short-term clinical outcome after acute symptomatic pulmonary embolism.
Thromb Haemost. 2008 Nov;100(5):937-42.

Deitelzweig SB, Becker R, Lin J, Benner J.
Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.
Thromb Haemost. 2008 Nov;100(5):810-20

Milbrink J, Bergqvist D.
The incidence of symptomatic venous thromboembolic events in orthopaedic surgery when using routine thromboprophylaxis.
Vasa. 2008 Nov;37(4):353-7

Franchini M, Mannucci PM.
Venous and arterial thrombosis: different sides of the same coin?
Eur J Intern Med. 2008 Nov;19(7):476-81. Epub 2008 Mar 20.

Heck CA, Brown CR, Richardson WJ.
Venous thromboembolism in spine surgery.
J Am Acad Orthop Surg. 2008 Nov;16(11):656-64.

Rubboli A, Halperin JL
Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'.
Thromb Haemost. 2008 Nov;100(5):752-3.

Kahn SR, Shrier I, Julian JA, Ducruet T, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Lamping DL, Johri M, Ginsberg JS.
Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis.
Ann Intern Med. 2008 Nov 18;149(10):698-707.

Glurich I, Burmester JK, Caldwell MD
Understanding the pharmacogenetic approach to warfarin dosing
Heart Fail Rev. 2008 Nov 8. [Epub ahead of print]

Thachil J, Gatt A, Martlew V.
Management of surgical patients receiving anticoagulation and antiplatelet agents.
Br J Surg. 2008 Nov 7;95(12):1437-1448. [Epub ahead of print]

Millar JA.
Rational thromboprophylaxis in medical inpatients: not quite there yet.
Med J Aust 2008 Nov 3;189(9):504-6.

Komotar RJ, Starke RM, Connolly ES Jr.
Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent.
Neurosurgery. 2008 Oct;63(4):N10-1

Laporte S, Mismetti P, Decousus H; RIETE Investigators
Clinical Predictors for Fatal Pulmonary Embolism in 15,520 Patients with Venous Thromboembolism: Findings from the Registro Informatizado de la Enfermedad Thrombo Embolica Venosa (RIETE) Registry.
J Vasc Surg. 2008 Oct;48(4):1063

Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S; on behalf of the ACTIVE W Investigators.
Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range.
Circulation. 2008 Oct 27. [Epub ahead of print]

Alonso-Coello P, Montori VM, Sola I, Schunemann HJ, Devereaux P, Charles C, Roura M, Diaz MG, Souto JC, Alonso R, Oliver S, Ruiz R, Coll-Vinent B, Diez AI, Gich I, Guyatt G.
Values and preferences in oral anticoagulation in patients with atrial fibrilation: physicians' and patients' perspectives. Protocol for a two-phase study.
BMC Health Serv Res. 2008 Oct 27;8(1):221. [Epub ahead of print]

Janin S, Meneveau N, Mahemuti A, Descotes-Genon V, Dutheil J, Chopard R, Seronde MF, Schiele F, Bernard Y, Bassand JP.
Safety and efficacy of fondaparinux as an adjunctive treatment to thrombolysis in patients with high and intermediate risk pulmonary embolism.
J Thromb Thrombolysis. 2008 Oct 25. [Epub ahead of print]

Nieuwlaat R, Connolly S.
Stroke prevention in atrial fibrillation: better use of anticoagulation and new agents will lead to improved outcomes.
Heart. 2008 Oct 24. [Epub ahead of print]

Eischer L, Gartner V, Schulman S, Kyrle PA, Eichinger S; for the AUREC-FVIII investigators (as listed in acknowledgements).
6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII.
Ann Hematol. 2008 Oct 18. [Epub ahead of print]

Walker AM, Bennett D.
Epidemiology and outcomes in patients with atrial fibrillation in the United States.
Heart Rhythm. 2008 Oct;5(10):1365-72. Epub 2008 Jul 17.

Cohen M, Hoekstra J.
The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention.
Am J Emerg Med. 2008 Oct;26(8):932-41.

Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, Flockhart DA, Arnett DK, Acton RT, Liu N.
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.
Pharmacogenomics. 2008 Oct;9(10):1445-58.

Parvizi J, Azzam K, Rothman RH.
Deep venous thrombosis prophylaxis for total joint arthroplasty: American Academy of Orthopaedic Surgeons guidelines.
J Arthroplasty. 2008 Oct;23(7 Suppl):2-5

Rose AJ, Ozonoff A, Henault LE, Hylek EM.
Warfarin for atrial fibrillation in community-based practise.
J Thromb Haemost. 2008 Oct;6(10):1647-54.

Furusho H, Takamura M, Takata S, Sakagami S, Hirazawa M, Kato T, Murai H, Okajima M, Kaneko S.
Current Status of Anticoagulation Therapy for Elderly Atrial Fibrillation Patients in Japan.
Circ J. 2008 Oct 14. [Epub ahead of print]

Sandercock PA, Counsell C, Kamal AK.
Anticoagulants for acute ischaemic stroke.
Cochrane Database Syst Rev. 2008 Oct 8;(4):CD000024

Testroote M, Stigter W, de Visser DC, Janzing H.
Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-leg immobilization.
Cochrane Database Syst Rev. 2008 Oct 8;(4):CD006681.

Ramos J, Perrotta C, Badariotti G, Berenstein G.
Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.
Cochrane Database Syst Rev. 2008 Oct 8;(4):CD005259.

Osborne NH, Wakefield TW, Henke PK.
Venous Thromboembolism in Cancer Patients Undergoing Major Surgery.
Ann Surg Oncol. 2008 Oct 8. [Epub ahead of print]

Tick LW, Kramer MH, Rosendaal FR, Faber WR, Doggen CJ.
Risk factors for post-thrombotic syndrome in patients with a first deep venous thrombosis.
J Thromb Haemost. 2008 Oct 4. [Epub ahead of print]

Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, Pinto D, Chen S, Bonacorsi S, Wong PC, Zhang D.
Apixaban metabolism and pharmacokinetics following oral administration to humans.
Drug Metab Dispos 2008 Oct 2. [Epub ahead of print]

Stangier J, Stähle H, Rathgen K, Roth W, Shakeri-Nejad K
Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment.
J Clin Pharmacol. 2008 Sep 30. [Epub ahead of print]

Lee A.
VTE in Patients with Cancer-Diagnosis, Prevention, and Treatment.
Thromb Res. 2008 Sep 26. [Epub ahead of print]

Kwong LM, Happe LE, Horblyuk R, Farrelly E.
Decreased venous thromboembolism with injectable vs oral anticoagulation after discharge for major orthopedic surgery.
J Arthroplasty 2008 Sep;23(6 Suppl 1):25-30.

Callaghan JJ, Warth LC, Hoballah JJ, Liu SS, Wells CW.
Evaluation of deep venous thrombosis prophylaxis in low-risk patients undergoing total knee arthroplasty.
J Arthroplasty 2008 Sep;23(6 Suppl 1):20-4.

Lopes RD, Piccini JP, Hylek EM, Granger CB, Alexander JH.
Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician.
J Thromb Thrombolysis 2008 Sep 21. [Epub ahead of print]

Shen AY, Chen W, Yao JF, Brar SS, Wang X, Go AS.
Effect of race/ethnicity on the efficacy of warfarin : potential implications for prevention of stroke in patients with atrial fibrillation.
CNS Drugs 2008;22(10):815-25.

Fuji T, Ochi T, Niwa S, Fujita S.
Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin.
J Orthop Sci. 2008 Sep;13(5):442-51. Epub 2008 Oct 9.

Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P, Bengel F, Brady AJ, Ferreira D, Janssens U, Klepetko W, Mayer E, Remy-Jardin M, Bassand JP, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Zamorano JL, Andreotti F, Ascherman M, Athanassopoulos G, De Sutter J, Fitzmaurice D, Forster T, Heras M, Jondeau G, Kjeldsen K, Knuuti J, Lang I, Lenzen M, Lopez-Sendon J, Nihoyannopoulos P, Perez Isla L, Schwehr U, Torraca L, Vachiery JL; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology.
Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC).
Eur Heart J 2008 Sep;29(18):2276-315. Epub 2008 Aug 30.

Trujillo-Santos J, Nieto JA, Tiberio G, Piccioli A, Di Micco P, Prandoni P, Monreal M; RIETE Registry.
Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry.
Thromb Haemost 2008 Sep;100(3):435-9

Wiedermann CJ, Stockner I.
Warfarin-induced bleeding complications - clinical presentation and therapeutic options.
Thromb Res 2008;122 Suppl 2:S13-8.

Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kälebo P, Muelhofer E, Misselwitz F, Eriksson BI.
Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Thromb Haemost 2008 Sep;100(3):453-61.

Righini M, Bounameaux H.
Clinical relevance of distal deep vein thrombosis.
Curr Opin Pulm Med 2008 Sep;14(5):408-13.

Douketis JD.
Prevention of venous thromboembolism in hospitalized medical patients: addressing some practical questions.
Curr Opin Pulm Med 2008 Sep;14(5):381-8.

Schellong SM.
Venous ultrasonography in symptomatic and asymptomatic patients: an updated review.
Curr Opin Pulm Med 2008 Sep;14(5):374-80.

Bauer KA.
New anticoagulants.
Curr Opin Hematol 2008 Sep;15(5):509-15.

Douketis J, Cook D, Meade M, Guyatt G, Geerts W, Skrobik Y, Albert M, Granton J, Hébert P, Pagliarello G, Marshall J, Fowler R, Freitag A, Rabbat C, Anderson D, Zytaruk N, Heels-Ansdell D, Crowther M; Canadian Critical Care Trials Group.
Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
Arch Intern Med 2008 Sep 8;168(16):1805-12.

Zhou Z, Hu D.
An Epidemiological Study on the Prevalence of Atrial Fibrillation in the Chinese Population of Mainland China.
J Epidemiol 2008 Sep 8. [Epub ahead of print]

Schelleman H, Limdi NA, Kimmel SE.
Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics.
Pharmacogenomics 2008 Sep;9(9):1331-46.

Seto AC, Kenyon K, Wittkowsky AK.
Discrepancies in identification of major bleeding events in patients taking warfarin.
Pharmacotherapy 2008 Sep;28(9):1098-103.

Tanne JH.
Most patients at risk of stroke fail to get adequate anticoagulation.
BMJ 2008 Sep 4;337:a1529. doi: 10.1136/bmj.a1529.

Hu D, Sun Y.
Epidemiology, risk factors for stroke, and management of atrial fibrillation in China.
Am Coll Cardiol 2008 Sep 2;52(10):865-8.

Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, Silver FL, Kapral MK.
Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated.
Stroke 2008 Aug 28. [Epub ahead of print]

Acosta S, Alhadad A, Svensson P, Ekberg O.
Epidemiology, risk and prognostic factors in mesenteric venous thrombosis.
Br J Surg 2008 Aug 21. [Epub ahead of print]

Gulseth MP, Michaud J, Nutescu EA.
Rivaroxaban: an oral direct inhibitor of factor Xa.
Am J Health Syst Pharm 2008 Aug 15;65(16):1520-9.

Bungard TJ, Koshman SL, Tsuyuki RT.
Patient preferences for ongoing warfarin management after receiving care by an anticoagulation management service.
Am J Health Syst Pharm 2008 Aug 15;65(16):1498-500.

Hylek EM, Frison L, Henault LE, Cupples A.
Disparate Stroke Rates on Warfarin Among Contemporaneous Cohorts With Atrial Fibrillation. Potential Insights Into Risk From a Comparative Analysis of SPORTIF III Versus SPORTIF V.
Stroke 2008 Aug 14.

Clark NP, Witt DM, Delate T, Trapp M, Garcia D, Ageno W, Hylek EM, Crowther MA.
Thromboembolic Consequences of Subtherapeutic Anticoagulation in Patients Stabilized on Warfarin Therapy: The Low INR Study.
Pharmacotherapy 2008 Aug;28(8):960-7

Levi M.
Self-management of anticoagulation
Expert Rev Cardiovasc Ther. 2008 Aug;6(7):979-85.

Aissaoui N, Martins E, Mouly S, Weber S, Meune C.
A meta-analysis of bed rest versus early ambulation in the management of pulmonary embolism, deep vein thrombosis, or both.
Int J Cardiol 2008 Aug 6. [Epub ahead of print]

Ageno W, Dentali F.
Venous thromboembolism and arterial thromboembolism. Many similarities, far beyond thrombosis per se.
Thromb Haemost 2008 Aug;100(2):181-3.

Gallus A.
Which patients with venous thromboembolism are at risk for fatal pulmonary embolism?
Nat Clin Pract Cardiovasc Med 2008 Aug 5. [Epub ahead of print]

Ho WK, Hankey GJ, Eikelboom JW.
The incidence of venous thromboembolism: a prospective, community-based study in Perth, Western Australia.
Med J Aust 2008 Aug 4;189(3):144-7.

Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T.
High Rate of Unprovoked Recurrent Venous Thrombosis is Associated with a High Thrombin Generating Potential in a Prospective Cohort Study.
J Thromb Haemost 2008 Aug 1. [Epub ahead of print]

Borris LC, Breindahl M, Lassen MR, Pap AF, Misselwitz F.
Differences in Urinary Prothrombin Fragment 1+2 Levels After Total Hip Replacement in Relation to Venous Thromboembolism and Bleeding Events.
J Thromb Haemost 2008 Aug 1. [Epub ahead of print]

Kakkar AK, Brenner B, Dahl OE, et al, for the RECORD2 investigators.
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled study.
The Lancet 2008; 372:31-39

Paauw JD, Borders H, Ingalls N, Boomstra S, Lambke S, Fedeson B, Goldsmith A, Davis AT.
The Incidence of PICC Line-Associated Thrombosis With and Without the Use of Prophylactic Anticoagulants.
JPEN J Parenter Enteral Nutr 2008 July-August;32(4):443-447.

Dunning J, Versteegh M, Fabbri A, Pavie A, Kolh P, Lockowandt U, Nashef SA; on behalf of the EACTS Audit and Guidelines Committee.
Guideline on antiplatelet and anticoagulation management in cardiac surgery.
Eur J Cardiothorac Surg 2008 Jul;34(1):73-92. Epub 2008 Mar 28.

Douen AG, Sabih M, Pageau N.
Thrombus detection by echocardiography in patients with acute ischemic stroke and chronic or new-onset atrial fibrillation.
J Stroke Cerebrovasc Dis 2008 Jul-Aug;17(4):208-11.

Fulco PP, Zingone MM, Higginson RT.
Possible antiretroviral therapy-warfarin drug interaction.
Pharmacotherapy 2008 Jul;28(7):945-9.

Verheugt FW.
Long-term anticoagulation in patients with coronary disease, and future developments.
Curr Opin Cardiol 2008 Jul;23(4):315-9

Brækkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Størmer J, Hansen JB.
Family history of myocardial infarction is an independent risk factor for venous thromboembolism - the Tromsø study.
J Thromb Haemost 2008 Jul 26. [Epub ahead of print]

Beri A, Punnam SR.
Anticoagulation in Patients with Acute Ischemic Stroke and Atrial Fibrillation-a Balance of Risks and Benefits.
Cardiovasc Drugs Ther 2008 Jul 21. [Epub ahead of print]

Savi P, Herault JP, Duchaussoy P, Millet L, Schaeffer P, Petitou M, Bono F, Herbert JM.
Reversible biotinylated oligosaccharides. A new approach for a better management of anticoagulant therapy.
J Thromb Haemost 2008 Jul 19. [Epub ahead of print]

Manzano-Fernández S, Pastor FJ, Marín F, Cambronero F, Caro C, Pascual-Figal DA, Garrido IP, Pinar E, Valdés M, Lip GY.
Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing.
Chest 2008 Jul 18. [Epub ahead of print]

Collen JF, Jackson JL, Shorr AF, Moores LK.
Prevention of venous thromboembolism in neurosurgery: a meta-analysis.
Chest 2008 Jul 18. [Epub ahead of print]

Akl EA, Barba M, Rohilla S, Terrenato I, Sperati F, Muti P, Schunemann HJ.
Low-Molecular-Weight Heparins are superior to Vitamin K Antagonists for the long term treatment of venous thromboembolism in patients with cancer: a Cochrane systematic review.
J Exp Clin Cancer Res 2008 Jul 18;27(1):21. [Epub ahead of print]

Barnes GD, Froehlich JB.
Anticoagulation: where we are and where we need to go.
J Thromb Thrombolysis 2008 Jul 18. [Epub ahead of print]

Khoobiar S, Mejevoi N, Kaid K, Boiangiu C, Setty S, Tanwir A, Khalid K, Cohen M.
Primary percutaneous coronary intervention for ST-elevation myocardial infarction using an intravenous and subcutaneous enoxaparin low molecular weight heparin regimen.
J Thromb Thrombolysis 2008 Jul 18. [Epub ahead of print]

Sandercock PA, Counsell C, Tseng MC.
Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke.
Cochrane Database Syst Rev 2008 Jul 16;(3):CD000119.

Audebert HJ, Schenk B, Tietz V, Schenkel J, Heuschmann PU.
Initiation of Oral Anticoagulation after Acute Ischaemic Stroke or Transient Ischaemic Attack: Timing and Complications of Overlapping Heparin or Conventional Treatment.
Cerebrovasc Dis 2008 Jul 15;26(2):171-177. [Epub ahead of print]

Camporese G, Bernardi E, Prandoni P, Noventa F, Verlato F, Simioni P, Ntita K, Salmistraro G, Frangos C, Rossi F, Cordova R, Franz F, Zucchetta P, Kontothanassis D, Andreozzi GM; KANT (Knee Arthroscopy Nadroparin Thromboprophylaxis) Study Group.
Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial.
Ann Intern Med 2008 Jul 15;149(2):73-82

Hallevi H, Albright KC, Martin-Schild S, Barreto AD, Savitz SI, Escobar MA, Gonzales NR, Noser EA, Illoh K, Grotta JC.
Anticoagulation After Cardioembolic Stroke: To Bridge or Not to Bridge?
Arch Neurol 2008 Jul 14. [Epub ahead of print]

Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A.
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor Rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study.
Blood 2008 Jul 11. [Epub ahead of print]

Eriksson BI, Borris LC, Friedman RJ, et al.
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
N Engl J Med 2008; 358:2765-2775.

Bottaro FJ, Elizondo MC, Doti C, Bruetman JE, Perez Moreno PD, Bullorsky EO, Ceresetto JM.
Efficacy of extended thrombo-prophylaxis in major abdominal surgery: What does the evidence show? A meta-analysis.
Thromb Haemost 2008 Jun;99(6):1104-11.

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators.
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
N Engl J Med. 2008; 358(26):2776-86.

Kakkar AK.
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer.
Clin Adv Hematol Oncol. 2008 Jun;6(6):416-417.

Gandolfo C, Balestrino M, Burrone A, Del Sette M, Finocchi C.
Stroke due to atrial fibrillation and the attitude to prescribing anticoagulant prevention in Italy. : A prospective study of a consecutive stroke population admitted to a comprehensive stroke unit.
J Neurol 2008 Jun 20. [Epub ahead of print]

Garcia DA, Witt DM, Hylek E, Wittkowsky AK, Nutescu EA, Jacobson A, Moll S, Merli GJ, Crowther M, Earl L, Becker RC, Oertel L, Jaffer A, Ansell JE.
Delivery of Optimized Anticoagulant Therapy: Consensus Statement from the Anticoagulation Forum (July/August).
Ann Pharmacother 2008 Jun 17. [Epub ahead of print]

Poller L, Keown M, Ibrahim S, Lowe G, Moia M, Turpie AG, Roberts C, van den Besselaar AM, van der Meer FJ, Tripodi A, Palareti G, Shiach C, Bryan S, Samama M, Burgess-Wilson M, Heagerty A, Maccallum P, Wright D, Jespersen J.
An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage.
J Thromb Haemost 2008 Jun;6(6):935-43.

Barantke M, Bonnemeier H.
Factor Xa inactivation in acute coronary syndrome.
Curr Pharm Des 2008;14(12):1186-90.

Franchini M, Mannucci PM
Interactions between genotype and phenotype in bleeding and thrombosis
Haematologica 2008; 93(5):649-52

Piccini JP, Patel MR, Mahaffey KW, Fox KA, Califf RM.
Rivaroxaban, an oral direct factor Xa inhibitor.
Expert Opin Investig Drugs 2008 Jun;17(6):925-937.

On behalf of the Botticelli investigators, the writing committee, Buller H, Deitchman D, Prins M, Segers A.
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep-vein thrombosis. The Botticelli DVT dose-ranging study.
J Thromb Haemost 2008 Jun 6. [Epub ahead of print]

Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S, Kornek G, Marosi C, Wagner O, Zielinski C, Pabinger I.
High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients - results from the Vienna Cancer and Thrombosis Study (CATS).
Blood. 2008 Jun 6. [Epub ahead of print]

Rahme E, Dasgupta K, Burman M, Yin H, Bernatsky S, Berry G, Nedjar H, Kahn SR.
Postdischarge thromboprophylaxis and mortality risk after hip-or knee-replacement surgery.
CMAJ 2008 Jun 3;178(12):1545-54.

Lip GY, Boos CJ.
Antithrombotic treatment in atrial fibrillation.
Postgrad Med J 2008 May;84(991):252-8.

O'Donnell M, Kearon C.
Perioperative management of oral anticoagulation.
Cardiol Clin 2008 May;26(2):299-309. PMID: 18407002 [PubMed - in process]

Bushnell BD, Anz AW, Bert JM.
Venous thromboembolism in lower extremity arthroscopy.
Arthroscopy 2008 May;24(5):604-11. Epub 2008 Jan 7.

Doggen CJ.
Thromboprophylaxis in cancer outpatients.
Blood 2008 May 15;111(10):4833.

Prandoni P, Tormene D, Perlati M, Brandolin B, Spiezia L.
Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders.
Expert Opin Investig Drugs 2008 May;17(5):773-7.

Gray E, Mulloy B, Barrowcliffe TW.
Heparin and low-molecular-weight heparin.
Thromb Haemost 2008 May;99(5):807-18.

Agnelli G, Eriksson BI, Cohen AT, Bergqvist D, Dahl OE, Lassen MR, Mouret P, Rosencher N, Andersson M, Bylock A, Jensen E, Boberg B; on behalf of the EXTEND Study Group.
Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran.
Thromb Res 2008 May 14. [Epub ahead of print]

Hermosillo AJ, Spinler SA.
Aspirin, Clopidogrel, and Warfarin: Is the Combination Appropriate and Effective or Inappropriate and Too Dangerous?
Ann Pharmacother 2008 May 13. [Epub ahead of print]

Devine EB, Hopefl AW, Wittkowsky AK.
Adherence to guidelines for the management of excessive warfarin anticoagulation.
J Thromb Thrombolysis. 2008 May 9. [Epub ahead of print]

Kahn SR, Shbaklo H, Lamping DL, Holcroft CA, Shrier I, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Johri M, Ginsberg JS.
Determinants of health-related quality of life during the two years following deep venous thrombosis.
J Thromb Haemost 2008 May 3. [Epub ahead of print]

Rubboli A, Halperin JL, Juhani Airaksinen KE, Buerke M, Eeckhout E, Freedman SB, Gershlick AH, Schlitt A, Fat Tse H, Verheugt FW, Lip GY.
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation.
Ann Med 2008 May 2:1-9. [Epub ahead of print]

Legnani C, Palareti G, Cosmi B, Cini M, Tosetto A, Tripodi A; for the PROLONG Investigators (on behalf of FCSA Italian Federation of Thrombosis Centers)
Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG stu
Haematologica 2008 Apr 28. [Epub ahead of print]

Akl E, Barba M, Rohilla S, Terrenato I, Sperati F, Muti P, Schünemann H.
Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer.
Cochrane Database Syst Rev 2008 Apr 16;(2):CD006650.

Magee K, Campbell S, Moher D, Rowe B.
Heparin versus placebo for acute coronary syndromes.
Cochrane Database Syst Rev 2008 Apr 16;(2):CD003462.

Lassen MR, Dahl O, Mismetti P, Zielske D, Turpie AG.
SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study.
J Am Coll Cardiol 2008 Apr 15;51(15):1498-504.

Prandoni P, Samama MM.
Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients.
Br J Haematol 2008 Apr 13; [Epub ahead of print]

The RE-MOBILIZE Writing Committee.
The Oral Thrombin Inhibitor Dabigatran Etexilate vs the North American Enoxaparin Regimen for the Prevention of Venous Thromboembolism after Knee Arthroplasty Surgery.
J Arthroplasty 2008 Apr 11. [Epub ahead of print]

Akl EA, Kamath G, Yosuico V, Kim SY, Barba M, Sperati F, Cook DJ, Schünemann HJ.
Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis.
Cancer 2008 Apr 10; [Epub ahead of print]

Meiltz A, Zimmermann M, Urban P, Bloch A; on behalf of the Association of Cardiologists of the Canton of Geneva.
Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world.
Europace 2008 Apr 10; [Epub ahead of print]

Baglin T.
Venous thromboembolism in hospitalised patients: a public health crisis?
Br J Haematol 2008 Apr 10; [Epub ahead of print]

Edwards JZ, Pulido PA, Ezzet KA, Copp SN, Walker RH, Colwell CW Jr.
Portable Compression Device and Low-Molecular-Weight Heparin Compared With Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Joint Arthroplasty.
J Arthroplasty 2008 Apr 1. [Epub ahead of print]

Karnicki K, Leadley RJ Jr, Baxi S, Peterson T, Wysokinski W, McBane RD 2nd.
Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis.
Thromb Haemost 2008 Apr;99(4):759-66.

Jowett S, Bryan S, Mahé I, Brieger D, Carlsson J, Kartman B, Nevinson M.
A multinational investigation of time and traveling costs in attending anticoagulation clinics.
Value Health 2008 Mar-Apr;11(2):207-12

Abdelhafiz AH, Wheeldon NM.
Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice.
Am J Geriatr Pharmacother 2008 Mar;6(1):1-11.

Bullock-Palmer RP, Weiss S, Hyman C.
Innovative approaches to increase deep vein thrombosis prophylaxis rate resulting in a decrease in hospital-acquired deep vein thrombosis at a tertiary-care teaching hospital.
J Hosp Med 2008 Mar;3(2):148-55.

Paskauskas S, Pundzius J, Barauskas G.
Venous thromboembolism and prophylaxis in cancer patients.
Medicina (Kaunas) 2008;44(3):175-81.

Stangier J.
Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.
Clin Pharmacokinet 2008;47(5):285-95.